1. Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer
   Jessica Pougoue Ketchemen et al, 2024, European Journal of Nuclear Medicine and Molecular Imaging CrossRef
2. Precision medicine in gastric cancer
   Patrizia Bonelli et al, 2019, World Journal of Gastrointestinal Oncology CrossRef
3. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage
   Kamila A. Marzec et al, 2015, Oncotarget CrossRef
4. Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
   Paola Menichini et al, 2021, Cells CrossRef
5. Anti-inflammatory effects of PRIMA-1MET (mutant p53 reactivator) induced by inhibition of nuclear factor-κB on rheumatoid arthritis fibroblast-like synoviocytes
   Mehrnoosh Adib et al, 2023, Inflammopharmacology CrossRef
6. OVER KANSERİ HÜCRELERİNDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİŞEN miRNA EKSPRESYON ANALİZİ
   Nilüfer İMİR et al, 2020, Sağlık Bilimleri Dergisi CrossRef
7. Research Progress of Mutant p53 as a Potential Therapeutic Target for Breast Cancer
   俊臻 周, 2021, Advances in Clinical Medicine CrossRef
8. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
   Phaik Ju Teoh et al, 2016, Oncotarget CrossRef
9. Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics
   Jessica Pougoue Ketchemen et al, 2023, British Journal of Cancer CrossRef
10. Targeting Oncogenic Mutant p53 for Cancer Therapy
    Alejandro Parrales et al, 2015, Frontiers in Oncology CrossRef
11. Novel Methylation Biomarkers for Colorectal Cancer Prognosis
    Alvaro Gutierrez et al, 2021, Biomolecules CrossRef